참고문헌
- Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 1993;94:646-650. https://doi.org/10.1016/0002-9343(93)90218-E
- Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 2006;17:1726-1733. https://doi.org/10.1007/s00198-006-0172-4
- Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 2006;17:1726-1733. https://doi.org/10.1007/s00198-006-0172-4
- Yood RA, Emani S, Reed JI, Lewis BE, Charpentier M, Lydick E. Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int 2003;14:965-968. https://doi.org/10.1007/s00198-003-1502-4
- McCombs JS, Thiebaud P, McLaughlin-Miley C, Shi J. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 2004;48:271-287. https://doi.org/10.1016/j.maturitas.2004.02.005
- Reginster JY, Felsenberg D, Cooper C, et al. A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate. Osteoporos Int 2006;17:159-166. https://doi.org/10.1007/s00198-005-1957-6
- Cramer JA, Amonkar MM, Hebborn A, Altman R. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005;21:1453-1460. https://doi.org/10.1185/030079905X61875
- Kendler D, Kung AW, Fuleihan Gel-H, et al. Patients with osteoporosis prefer once weekly to once daily dosing with alendronate. Maturitas 2004;48:243-251. https://doi.org/10.1016/j.maturitas.2003.12.012
- Barrett J, Worth E, Bauss F, Epstein S. Ibandronate: a clinical pharmacological and pharmacokinetic update. J Clin Pharmacol 2004;44:951-965. https://doi.org/10.1177/0091270004267594
- Frampton JE, Perry CM. Ibandronate: a review of its use in the management of postmenopausal osteoporosis. Drugs 2008;68:2683-2707. https://doi.org/10.2165/0003495-200868180-00011
- Rossini M, Viapiana O, Gatti D, Adami S. Once-monthly oral ibandronate in postmenopausal osteoporosis: translation and updated review. Clin Ther 2009;31:1497-1510. https://doi.org/10.1016/j.clinthera.2009.07.018
- Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12. https://doi.org/10.1016/0197-2456(95)00134-4
- Davey Smith G, Egger M. Meta-analyses of randomised controlled trials. Lancet 1997;350:1182.
- Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-1558. https://doi.org/10.1002/sim.1186
- Emkey R, Delmas PD, Bolognese M, et al. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study. Clin Ther 2009;31:751-761. https://doi.org/10.1016/j.clinthera.2009.04.018
- McClung MR, Bolognese MA, Sedarati F, Recker RR, Miller PD. Efficacy and safety of monthly oral ibandronate in the prevention of postmenopausal bone loss. Bone 2009;44:418-422. https://doi.org/10.1016/j.bone.2008.09.011
- Lewiecki EM, Keaveny TM, Kopperdahl DL, et al. Once-monthly oral ibandronate improves biomechanical determinants of bone strength in women with postmenopausal osteoporosis. J Clin Endocrinol Metab 2009;94:171-180. https://doi.org/10.1210/jc.2008-1807
- Hadji P, Minne H, Pfeifer M, et al. Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: A randomized, crossover study (BALTO II). Joint Bone Spine 2008;75:303-310. https://doi.org/10.1016/j.jbspin.2007.07.011
- Miller PD, Epstein S, Sedarati F, Reginster JY. Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study. Curr Med Res Opin 2008;24:207-213. https://doi.org/10.1185/030079908X253889
- Cooper A, Drake J, Brankin E; PERSIST Investigators. Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. Int J Clin Pract 2006;60:896-905. https://doi.org/10.1111/j.1742-1241.2006.01059.x
- Emkey R, Koltun W, Beusterien K, et al. Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin 2005;21:1895-1903. https://doi.org/10.1185/030079905X74862
- Reginster JY, Adami S, Lakatos P, et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis 2006;65:654-661. https://doi.org/10.1136/ard.2005.044958
- Stakkestad JA, Lakatos P, Lorenc R, Sedarati F, Neate C, Reginster JY. Monthly oral ibandronate is effective and well tolerated after 3 years: the MOBILE long-term extension. Clin Rheumatol 2008;27:955-960. https://doi.org/10.1007/s10067-007-0824-6
- Miller PD, McClung MR, Macovei L, et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res 2005;20:1315-1322. https://doi.org/10.1359/JBMR.050313
- Reginster JY, Wilson KM, Dumont E, Bonvoisin B, Barrett J. Monthly oral ibandronate is well tolerated and efficacious in postmenopausal women: results from the monthly oral pilot study. J Clin Endocrinol Metab 2005;90:5018-5024. https://doi.org/10.1210/jc.2004-1750
- Epstein S, Jeglitsch M, McCloskey E. Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg. Curr Med Res Opin 2009;25:2951-2960. https://doi.org/10.1185/03007990903361307
- Harris ST, Blumentals WA, Miller PD. Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies. Curr Med Res Opin 2008;24:237-245. https://doi.org/10.1185/030079908X253717
- Pyon EY. Once-monthly ibandronate for postmenopausal osteoporosis: review of a new dosing regimen. Clin Ther 2006;28:475-490. https://doi.org/10.1016/j.clinthera.2006.04.006
- Sebba AI, Emkey RD, Kohles JD, Sambrook PN. Ibandronate dose response is associated with increases in bone mineral density and reductions in clinical fractures: results of a metaanalysis. Bone 2009;44:423-427. https://doi.org/10.1016/j.bone.2008.10.052
피인용 문헌
- Meta-analysis of randomized controlled trials of bosentan for treatment of pulmonary arterial hypertension vol.28, pp.6, 2011, https://doi.org/10.3904/kjim.2013.28.6.701
- The Clinical Significance of Simplified Scoring Criteria as a Diagnostic Tool for Overlap Syndrome in Korea vol.84, pp.2, 2011, https://doi.org/10.3904/kjm.2013.84.2.211
- The CTLA-4 +49 A/G, CT60 A/G and PTPN22 1858 C/T polymorphisms and susceptibility to vitiligo: a meta-analysis vol.40, pp.4, 2011, https://doi.org/10.1007/s11033-012-2370-9
- Associations between FCGR2A rs1801274, FCGR3A rs396991, FCGR3B NA1/NA2 polymorphisms and periodontitis: a meta-analysis vol.40, pp.8, 2011, https://doi.org/10.1007/s11033-013-2599-y
- Toll-like receptor (TLR) and matrix metalloproteinase (MMP) polymorphisms and periodontitis susceptibility: a meta-analysis vol.40, pp.8, 2011, https://doi.org/10.1007/s11033-013-2616-1
- Association between tumor necrosis factor-α promoter −308 A/G, −238 A/G, interleukin-6 −174 G/C and −572 G/C polymorphisms and periodontal disease: a meta-analysis vol.40, pp.8, 2011, https://doi.org/10.1007/s11033-013-2621-4
- Associations between the insertion/deletion polymorphism of the angiotensin-converting enzyme and susceptibility to aortic aneurysms: A meta-analysis vol.16, pp.1, 2011, https://doi.org/10.1177/1470320313485897
- Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from vol.26, pp.10, 2015, https://doi.org/10.1007/s00198-015-3164-4
- Body Mass Index May Positively Correlate with Bone Mineral Density of Lumbar Vertebra and Femoral Neck in Postmenopausal Females vol.22, pp.None, 2011, https://doi.org/10.12659/msm.895512
- Factors associated with high 24-month persistence with denosumab: results of a real-world, non-interventional study of women with postmenopausal osteoporosis in Germany, Austria, Greece, and Belgium vol.12, pp.1, 2011, https://doi.org/10.1007/s11657-017-0351-2
- Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline vol.35, pp.18, 2011, https://doi.org/10.1200/jco.2016.70.7257
- Efficacy and safety of bisphosphonates in management of low bone density in inflammatory bowel disease : A meta-analysis vol.96, pp.3, 2011, https://doi.org/10.1097/md.0000000000005861
- Undertreatment of osteoporosis following hip fracture: a retrospective, observational study in Singapore vol.15, pp.1, 2011, https://doi.org/10.1007/s11657-020-00816-2